• In combination with ASA, prasugrel, compared with clopidogrel, reduced the risk of vascular events in NSTEACS patients treated by PCI, when administered after coronary anatomy has been defined
• The risk of major, life-threatening, and fatal bleeding was increased by prasugrel at a dose of 10 mg, particularly in those with:
  • Age ≥ 75 years
  • Body weight < 60 kg
• Prasugrel is contraindicated in patients with a prior history of cerebrovascular disease
• STEMI patients treated with PCI had similar benefits in reducing vascular events without increasing major bleeding
• No benefit for prasugrel over clopidogrel was demonstrated in patients managed medically following NSTEAC